TWI857071B - 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物 - Google Patents

2,3,5-三取代吡唑并[1,5-a]嘧啶化合物 Download PDF

Info

Publication number
TWI857071B
TWI857071B TW109118850A TW109118850A TWI857071B TW I857071 B TWI857071 B TW I857071B TW 109118850 A TW109118850 A TW 109118850A TW 109118850 A TW109118850 A TW 109118850A TW I857071 B TWI857071 B TW I857071B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
cancer
hydroxyalkyl
independently selected
Prior art date
Application number
TW109118850A
Other languages
English (en)
Chinese (zh)
Other versions
TW202110850A (zh
Inventor
喬伊爾 華里 比提
山謬 勞瑞 卓爾
傑瑞米 湯瑪士 安德烈 佛尼爾
珍那 梨 傑佛瑞
肯尼斯 維克特 勞森
曼摩漢 瑞迪 賴勒提
雅圖 喀連那維卡 梅蓮恩
吉勞米 瑪塔
迪倫 哈汀 邁爾斯
傑 派翠克 包爾斯
荷森 厄爾 莎瑞菲
崔恩 瑞亞納恩 湯馬士
雪蕾 閆
Original Assignee
美商阿克思生物科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商阿克思生物科學有限公司 filed Critical 美商阿克思生物科學有限公司
Publication of TW202110850A publication Critical patent/TW202110850A/zh
Application granted granted Critical
Publication of TWI857071B publication Critical patent/TWI857071B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0636—Irradiating the whole body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109118850A 2019-06-04 2020-06-04 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物 TWI857071B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857148P 2019-06-04 2019-06-04
US62/857,148 2019-06-04

Publications (2)

Publication Number Publication Date
TW202110850A TW202110850A (zh) 2021-03-16
TWI857071B true TWI857071B (zh) 2024-10-01

Family

ID=73652950

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109118850A TWI857071B (zh) 2019-06-04 2020-06-04 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物

Country Status (11)

Country Link
US (1) US12410170B2 (enExample)
EP (1) EP3980010A4 (enExample)
JP (1) JP7665534B2 (enExample)
KR (1) KR20220047247A (enExample)
CN (1) CN114206332B (enExample)
AR (1) AR119088A1 (enExample)
AU (1) AU2020288610A1 (enExample)
CA (1) CA3142712A1 (enExample)
TW (1) TWI857071B (enExample)
UY (1) UY38742A (enExample)
WO (1) WO2020247496A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
WO2022226052A1 (en) * 2021-04-20 2022-10-27 The Regents Of The University Of Michigan Pi3k inhibitors, nanoformulations, and uses thereof
WO2022246177A1 (en) 2021-05-21 2022-11-24 Arcus Biosciences, Inc. Axl compounds
EP4341262A1 (en) 2021-05-21 2024-03-27 Arcus Biosciences, Inc. Axl inhibitor compounds
TW202325279A (zh) 2021-10-29 2023-07-01 美商阿克思生物科學有限公司 HIF-2α抑制劑及其使用方法
WO2023165551A1 (zh) * 2022-03-02 2023-09-07 上海海雁医药科技有限公司 六元芳环并吡咯酮衍生物、其药物组合物及应用
CN119156228A (zh) 2022-05-02 2024-12-17 艾库斯生物科学有限公司 抗tigit抗体及其用途
EP4554680A1 (en) 2022-07-15 2025-05-21 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
CN119768404A (zh) * 2022-09-01 2025-04-04 上海海雁医药科技有限公司 杂芳基取代的吡啶并吡咯酮衍生物、其药物组合物及应用
TW202421150A (zh) 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體
EP4602041A1 (en) 2022-10-14 2025-08-20 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
EP4705292A1 (en) 2023-05-05 2026-03-11 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024243502A1 (en) 2023-05-25 2024-11-28 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4788432A1 (en) 2023-10-06 2026-08-12 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2025146216A1 (zh) * 2024-01-05 2025-07-10 成都赜灵生物医药科技有限公司 六并五氮杂环酰胺类化合物及其用途
WO2025193759A1 (en) 2024-03-12 2025-09-18 Gilead Sciences, Inc. Solid forms of an azolopyrimidine compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200900404A (en) * 2007-03-21 2009-01-01 Wyeth Corp Pyrazolopyrimidine analogs and their use as mTOR kinase and PI3 kinase inhibitors
US20170088553A1 (en) * 2015-09-14 2017-03-30 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
CN108017641A (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
JP2009523769A (ja) 2006-01-23 2009-06-25 ラボラトワール セローノ ソシエテ アノニム チアゾール誘導体及びこれらの使用
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
UA102828C2 (en) 2007-11-27 2013-08-27 Целльзом Лимитед Amino triazoles as p13k inhibitors
GB0812309D0 (en) 2008-07-03 2008-08-13 Ucb Pharma Sa Therapeutic agents
TW201018685A (en) 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
RU2573569C2 (ru) 2009-12-22 2016-01-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
HK1214159A1 (zh) 2012-11-08 2016-07-22 Rhizen Pharmaceuticals S.A. 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
RU2675814C2 (ru) 2013-09-25 2018-12-25 Вертекс Фармасьютикалз Инкорпорейтед 6,7-ДИГИДРО-5Н-ПИРРОЛО[3,4-b]ПИРИДИН-5-ОН, ПОЛЕЗНЫЙ В КАЧЕСТВЕ СЕЛЕКТИВНОГО ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ-ГАММА
EP3964507A1 (en) * 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
RS60450B1 (sr) 2014-09-03 2020-07-31 Rhizen Pharmaceuticals Sa Postupak za tretiranje i kompozicije koje sadrže dvojni inhibitor pi3k delta-gama kinaze i kortikosteroid
WO2016064958A1 (en) 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
RS63359B1 (sr) 2015-11-06 2022-07-29 Incyte Corp Heterociklična jedinjenja kao inhibitori pi3k-gama
BR112018068075A2 (pt) * 2016-03-10 2019-01-08 Astrazeneca Ab inibidores de fosfatidilinositol 3-quinase gama
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
EA036176B1 (ru) 2016-09-22 2020-10-09 Астразенека Аб Производные 5-[2-(пиридин-2-иламино)-1,3-тиазол-5-ил]-2,3-дигидро-1h-изоиндол-1-она и их применение в качестве двойных ингибиторов фосфатидилинозитол-3-киназ дельта и гамма
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200900404A (en) * 2007-03-21 2009-01-01 Wyeth Corp Pyrazolopyrimidine analogs and their use as mTOR kinase and PI3 kinase inhibitors
US20170088553A1 (en) * 2015-09-14 2017-03-30 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
CN108017641A (zh) * 2016-11-02 2018-05-11 叶宝欢 吡唑并嘧啶化合物作为pi3k抑制剂及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 COME JON H. ET AL: "Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase [gamma] (PI3K[gamma]) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)" JOURNAL OF MEDICINAL CHEMISTRY vol. 61, no. 12 30 May 2018 pages 5245 - 5256
期刊 COME JON H. ET AL: "Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase [gamma] (PI3K[gamma]) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)" JOURNAL OF MEDICINAL CHEMISTRY vol. 61, no. 12 30 May 2018 pages 5245 - 5256;期刊 PEMBERTON NILS ET AL: "Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-[gamma] Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY vol. 61, no. 12 31 May 2018 pages 5435 - 5441 *
期刊 PEMBERTON NILS ET AL: "Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-[gamma] Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY vol. 61, no. 12 31 May 2018 pages 5435 - 5441

Also Published As

Publication number Publication date
JP7665534B2 (ja) 2025-04-21
WO2020247496A1 (en) 2020-12-10
CA3142712A1 (en) 2020-12-10
AR119088A1 (es) 2021-11-24
EP3980010A4 (en) 2023-06-07
AU2020288610A1 (en) 2022-01-27
CN114206332A (zh) 2022-03-18
CN114206332B (zh) 2024-08-23
TW202110850A (zh) 2021-03-16
EP3980010A1 (en) 2022-04-13
US20230024302A1 (en) 2023-01-26
JP2022535120A (ja) 2022-08-04
US12410170B2 (en) 2025-09-09
KR20220047247A (ko) 2022-04-15
UY38742A (es) 2020-12-31

Similar Documents

Publication Publication Date Title
CN114206332B (zh) 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物
JP7648828B2 (ja) Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物
KR102809468B1 (ko) 피리돈 a2r 길항제
TWI828800B (zh) Arg1及/或arg2之抑制劑
KR102656571B1 (ko) 아르기나아제 억제제
ES2953349T3 (es) Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
HK40068316B (zh) 2，3，5-三取代吡唑并[1，5-a]嘧啶化合物
HK40068316A (en) 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
HK40101362A (en) Azolopyrimidine for the treatment of cancer-related disorders
HK40054296B (en) Pyridone a2r antagonists
HK40054296A (en) Pyridone a2r antagonists
HK40055891B (zh) 吡啶酮a2r拮抗剂
HK40055891A (en) Pyridone a2r antagonists
HK40024629B (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
HK40024629A (en) Quinazoline-pyridine derivatives for the treatment of cancer-related disorders

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees